Vivimed Labs Limited Files SEBI Compliance Certificate for Q1 FY27
Vivimed Labs Limited submitted a certificate confirming compliance with SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The RTA confirmed dematerialization actions were completed within the stipulated timeframe.
This is a standard regulatory compliance filing and has no direct impact on the company's operations or financial performance.
The announcement is a routine compliance filing and does not contain any new financial information or strategic developments that would impact the company's outlook.
Vivimed Labs Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate was received from the company's Registrar and Share Transfer Agent (RTA), Aarthi Consultants Private Limited.
Aarthi Consultants Private Limited, a SEBI registered Category-I RTA, confirmed that for the period from April 1, 2026, to June 30, 2026, all actions required under Regulation 74(5) were completed within 15 days of receiving the securities for dematerialization. These actions include the dematerialization of securities, cancellation of original certificates, and updating the depository as the registered owner.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.